The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | The impact of donor KIR genotypes on alloSCT outcomes in AML/MDS, and the value of biobanks
Johannes Schetelig, MD, MSc, University Hospital TU Dresden, Dresden, Germany, discusses a study investigating the impact of donor killer-cell immunoglobulin-like receptor (KIR) genotypes on allogeneic stem cell transplantation (alloSCT) outcomes in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The study failed to validate any of the previously proposed models that were predictive of patient outcomes following alloSCT. Prof. Schetelig goes on to discuss a biobank of more than 50,000 donor samples supported by German transplant and collection centers, which is open for use by researchers from around the world. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
